12.05
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Bausch + Lomb’s LuxLife Intraocular Lens Gains European CE Mark Approval - TipRanks
Bausch + Lomb (BLCO) Receives CE Mark for LuxLife Intraocular Lens | BLCO Stock News - GuruFocus
Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens - Stock Titan
Bausch & Lomb (BLCO) Price Target Lowered by Morgan Stanley | BLCO Stock News - GuruFocus
Bausch & Lomb stock target cut to $15 at H.C. Wainwright By Investing.com - Investing.com South Africa
Bausch & Lomb stock target cut to $15 at H.C. Wainwright - Investing.com Nigeria
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwr - GuruFocus
Bausch & Lomb (BLCO) Receives Adjusted Price Target by HC Wainwright & Co. | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Cut by Analyst Amid Tariff Concerns | BLCO Stock News - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Pr - GuruFocus
Citi Maintains Neutral Rating on Bausch & Lomb (BLCO), Lowers Price Target | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Shares Plunge After Weak Q1 2025 Results - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Evercore ISI Group - GuruFocus
Bausch & Lomb (BLCO) Target Price Lowered by Wells Fargo | BLCO Stock News - GuruFocus
Bausch + Lomb Corporation (NYSE:BLCO) Q1 2025 Earnings Call Transcript - Insider Monkey
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Press - GuruFocus
Bausch + Lomb (BLCO) Sees Adjusted Price Target Amidst Earnings Update | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectati - GuruFocus
Bausch + Lomb (BLCO) Faces Price Target Cut Amid Financial Pressures | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Price Target Reduced by Citi After Q1 Repor - GuruFocus
Bausch + Lomb (BLCO) Misses Revenue Expectations in Q1, Shares D - GuruFocus
Bausch + Lomb (BLCO) Misses Q1 Estimates, Lowers Growth Outlook - GuruFocus
Bausch & Lomb Reports Weak Start to 2025 as enVista Recall, Tariffs, and Drug Pricing Cause Concerns - Morningstar
Bausch & Lomb Corp SEC 10-Q Report - TradingView
Bausch + Lomb stock hits 52-week low at $10.46 By Investing.com - Investing.com India
Bausch + Lomb stock hits 52-week low at $10.46 - Investing.com Australia
Bausch + Lomb shares tumble as Q1 earnings miss expectations By Investing.com - Investing.com Canada
Bausch + Lomb shares tumble as Q1 earnings miss expectations - Investing.com
Bausch + Lomb Announces First-Quarter 2025 Results - BioSpace
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Bausch + Lomb Reports Q1 2025 Revenue Growth Amid Challenges - TipRanks
Bausch + Lomb Q1 2025 slides: Revenue grows 5% despite enVista recall impact - Investing.com
Bausch + Lomb (BLCO) Updates FY25 Financial Outlook | BLCO Stock News - GuruFocus
Bausch + Lomb (BLCO) Reports Q1 Revenue Slightly Below Expectations | BLCO Stock News - GuruFocus
Bausch + Lomb: Q1 Earnings Snapshot - Barchart.com
Bausch + Lomb Q1 2025 Financial Results - TradingView
Wells Fargo maintains Bausch & Lomb stock with $15 target By Investing.com - Investing.com Canada
Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings - Barchart.com
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall - BioSpace
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb resumes enVista IOL production after recall - Investing.com
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for - MSN
Billionaire Carl Icahn builds 34% economic interest in Bausch Health - Reuters
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch upgrades Bausch + Lomb rating, maintains evolving watch By Investing.com - Investing.com Canada
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch & Lomb Agrees to End Vitamin-Patent Suit Ahead of Trial - Bloomberg Law News
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Bausch + Lomb Recalls Certain EnVista Intraocular Lenses - Nasdaq
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & SuppliesSpecialty Segment - Yahoo Finance
Bausch + Lomb Gears Up For Q1 2025 Results Announcement - Finimize
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):